ATLANTA, GA – – (Globe Newswire – September 9, 2024) – – A shareholder class action lawsuit has been filed against Agenus Inc. (“Agenus” or “the Company”) (NASDAQ: AGEN). The lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s business, operations, and prospects, including allegations that: (i) the combination therapy of botensilimab and balstilimab was less effective than Defendants had led investors to believe; and (ii) accordingly, botensilimab and balstilimab’s clinical results, as well as their regulatory and commercial prospects, were overstated.

If you bought shares of Agenus between January 23, 2023 through July 17, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/agenus/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is November 5, 2024.